Transdermal Progesterone Solubilization via Co-Solvents
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current transdermal hormone replacement therapies face challenges in solubilizing natural progesterone due to its insolubility, leading to higher dosage requirements and limited commercialization of patches using natural progesterone, while prevailing technologies rely on synthetic progestins, which may have different side effects and patient compliance issues with separate estrogen and progesterone dosing regimens.
Innovation Solution
Development of transdermal pharmaceutical formulations that solubilize progesterone and optionally combine it with estrogen, allowing for cyclic/sequential and continuous-combined dosing regimes via transdermal patches, packaged in a single package to improve patient compliance and reduce side effects by mimicking natural hormone delivery.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If natural progesterone is used in transdermal formulations, then patient compliance and side effect profile improve, but solubility and formulation stability worsen
Solution Approach 1:
The patent uses solubilizing agents and co-solvents as intermediary substances to bridge the incompatibility between natural progesterone and the transdermal patch matrix. These intermediaries enable the insoluble progesterone to be incorporated into the patch formulation while maintaining its therapeutic efficacy and improving patient compliance through natural hormone replacement.
Solution Approach 2:
The patent modifies the physical and chemical parameters of the progesterone formulation by changing its solubility characteristics through the use of specific solvents, co-solvents, and solubilizing agents. This allows the natural progesterone to be delivered at physiologically relevant doses through transdermal absorption without compromising formulation stability.
2Quantity of substance
If synthetic progestins are used instead of natural progesterone, then formulation solubility improves, but side effects and patient compliance worsen
Solution Approach 1:
The patent converts the apparent disadvantage of natural progesterone's poor solubility into a benefit by developing sophisticated solubilization techniques. This approach allows the use of natural progesterone with its favorable side effect profile and patient acceptance, while overcoming the solubility challenge through innovative formulation science rather than resorting to synthetic alternatives.
3Adaptability or versatility
If separate estrogen and progesterone dosing regimens are used, then dosing flexibility improves, but patient compliance and treatment complexity worsen
Solution Approach 1:
The patent combines estrogen and progesterone into a single transdermal patch formulation, merging two separate dosing regimens into one unified delivery system. This integration maintains the ability to independently adjust hormone doses while dramatically simplifying patient compliance by eliminating the need for multiple separate applications or coordination of different dosing schedules.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The solubilized progesterone and estrogen formulations enhance patient compliance and reduce side effects by providing consistent hormone delivery, addressing the limitations of existing therapies with natural progesterone and synthetic progestins, and improving the treatment of menopause-related symptoms.
Implementation Method 1
transdermal delivery systems...delivering a hormone, or a combination of hormones, through the skin
Data Source
Figure 1
Figure 2~3
Figure 4
AI summary
Hormone replacement therapies are provided comprising solubilized progesterone alone and optionally with an estrogen, cyclic/sequential and continuous-combined dosing, and administered via transdermal HRT delivery systems.